The nod is subject to amendment in how primary efficacy endpoint for symptomatic cases be studied in Phase 3 trials, the panel further stated.
from Hindustan Times - india https://ift.tt/2HoFUiA
Home / Hindustan Times - india
/ Covaxin: Bharat Biotech gets nod from DCGI panel for Phase III trials
Subscribe to:
Post Comments
(
Atom
)
0 comments:
Post a Comment